Evidence map›Paper›PMID 22479381›Full record

ArticlePloS one2012

A sensitive branched DNA HIV-1 signal amplification viral load assay with single day turnaround.

Mark A Baumeister, Nan Zhang, Hilda Beas, Jesse R Brooks, Jesse A Canchola, Carlo Cosenza, Felix Kleshik, Vinod Rampersad, Johan Surtihadi, Thomas R Battersby

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Nucleic acid testing and molecular characterization of HIV infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Review
  2. Nucleic Acid-based approaches for detection of viral hepatitis.Jundishapur journal of microbiology · 2015
    Review
  3. Article
  4. Diagnostic molecular microbiology: a 2013 snapshot.Clinics in laboratory medicine · 2013
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mark A BaumeisterSiemens Healthcare Diagnostics Inc., Berkeley, California, United States of America.
Nan Zhang
Hilda Beas
Jesse R Brooks
Jesse A Canchola
Carlo Cosenza
Felix Kleshik
Vinod Rampersad
Johan Surtihadi
Thomas R Battersby
University of Houston · USSiemens Healthcare (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Branched DNA (bDNA) is a signal amplification technology used in clinical and research laboratories to quantitatively detect nucleic acids. An overnight incubation is a significant drawback of highly sensitive bDNA assays. The VERSANT® HIV-1 RNA 3.0 Assay (bDNA) ("Versant Assay") currently used in clinical laboratories was modified to allow shorter target incubation, enabling the viral load assay to be run in a single day. To dramatically reduce the target incubation from 16-18 h to 2.5 h, composition of only the "Lysis Diluent" solution was modified. Nucleic acid probes in the assay were unchanged. Performance of the modified assay (assay in development; not commercially available) was evaluated and compared to the Versant Assay. Dilution series replicates (>950 results) were used to demonstrate that analytical sensitivity, linearity, accuracy, and precision for the shorter modified assay are comparable to the Versant Assay. HIV RNA-positive clinical specimens (n = 135) showed no significant difference in quantification between the modified assay and the Versant Assay. Equivalent relative quantification of samples of eight genotypes was demonstrated for the two assays. Elevated levels of several potentially interfering endogenous substances had no effect on quantification or specificity of the modified assay. The modified assay with drastically improved turnaround time demonstrates the viability of signal-amplifying technology, such as bDNA, as an alternative to the PCR-based assays dominating viral load monitoring in clinical laboratories. Highly sensitive bDNA assays with a single day turnaround may be ideal for laboratories with especially stringent cost, contamination, or reliability requirements.

Indexed as

Branched DNA Signal Amplification AssayHIV-1HIV InfectionsHumansNucleic Acid Amplification TechniquesPolymerase Chain ReactionReagent Kits, DiagnosticReproducibility of ResultsSensitivity and SpecificityTime FactorsViral LoadReagent Kits, Diagnostic

Identifiers

PMID22479381
PMCPMC3314011
OpenAlexW2050614335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.